Replies to post #24344 on Ocata Therapeutics Inc fka OCAT

[rumit]

For example, this paragraph on their website doesn't even mention iPSC as a source.

We are focused on developing universal, donorless red blood cells in order to help alleviate shortages of blood types encountered in emergency situations. Using our hemangioblast technology, we have shown that functional, oxygen-carrying erythrocytes (red blood cells) can be derived from hESCs (Blood, 112: 4475-4484, 2008) and are now optimizing the system for improved efficiency and large scale production.

http://www.steminternational.com/our-focus/transfusable-blood-components/

[rocky301]

rumit,

I am with you, it seems very confusing. Not long ago Caldwell stated iPS was a science project. Then the report from ACT that iPS cells showed early aging and the hesc's were the route to go. It has been a mixed message from my standpoint. The o-negative "start" seems to be the key. Here are some links that may help or just confuse.

FEB 2010 BioWorld
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46624354

My follow up to article
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46625633

"The firm had a solicitation at the Department of Defense for $5.6 million to create universal blood, but none of the Bush lines were O negative, and ACT was unable to get the White House to sign off on permitting the use of the company's single blastomere technique."
http://investorshub.advfn.com/boards/read_msg.aspx
message_id=46950661